Positron emission tomography in diagnosis and differential diagnosis of Parkinson's disease

Neurodegenerative Diseases

Volumn 7, Issue 5, 2010, Pages 330-340

  Tatsch, Klaus ^a  

^a Municipal Hospital of Karlsruhe Inc   (Germany)

Author keywords

Amyloid imaging; Cardiac sympathetic denervation; Differential diagnosis; Dopaminergic system; Glucose metabolism; Inflammation; Parkinson's disease; Positron emission tomography

Indexed keywords

NEUROTRANSMITTER; DOPAMINE;

DIFFERENTIAL DIAGNOSIS; DOPAMINERGIC ACTIVITY; EARLY DIAGNOSIS; GLUCOSE METABOLISM; HUMAN; MOLECULAR IMAGING; PARKINSON DISEASE; PARKINSONISM; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; ANIMAL; LEWY BODY DISEASE; NEURODEGENERATIVE DISEASES; PHYSIOLOGY; SCINTISCANNING;

ANIMALS; DIAGNOSIS, DIFFERENTIAL; DOPAMINE; EARLY DIAGNOSIS; HUMANS; LEWY BODY DISEASE; NEURODEGENERATIVE DISEASES; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY;

EID: 77954293172     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000314499     Document Type: Review

References (94)

1. Hughes AJ, Daniel SE, Kilford L, Lees AJ: Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181-184.
2. Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ: What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. 1992. Neurology 2001; 57:S34-S38.
3. Marshall VL, Reininger CB, Marquardt M, et al: Parkinson's disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: a 3 year European multicenter study with repeat [123I]FP-CIT SPECT. Mov Disord 2009; 24: 500-508.
4. Meara J, Bhowmick BK, Hobson P: Accuracy of diagnosis in patients with presumed Parkinson's disease. Age Ageing 1999; 28: 99-102.
5. Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ: The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002; 125: 861-870.
6. Au WL, Adams JR, Troiano A, Stoessl AJ: Neuroimaging in Parkinson's disease. J Neural Transm Suppl 2006: 241-248.
7. Seppi K, Poewe W: Brain magnetic resonance imaging techniques in the diagnosis of parkinsonian syndromes. Neuroimaging Clin N Am 20: 29-55.
8. Brooks DJ: Neuroimaging in Parkinson's disease. NeuroRx 2004; 1: 243-254.
9. Booij J, Tissingh G, Winogrodzka A, van Royen EA: Imaging of the dopaminergic neurotransmission system using single-photon emission tomography and positron emission tomography in patients with parkinsonism. Eur J Nucl Med 1999; 26: 171-182.
10. Nikolaus S, Antke C, Kley K, et al: Investigating the dopaminergic synapse in vivo. I. Molecular imaging studies in humans. Rev Neurosci 2007; 18: 439-472. (Pubitemid 351184054)
11. Frey KA, Koeppe RA, Kilbourn MR: Imaging the vesicular monoamine transporter. Adv Neurol 2001; 86: 237-247.
12. Koeppe RA, Gilman S, Junck L, Wernette K, Frey KA: Differentiating Alzheimer's disease from dementia with Lewy bodies and Parkinson's disease with (+)-[11C]dihydrotetrabenazine positron emission tomography. Alzheimers Dement 2008; 4:S67-S76.
13. Okamura N, Villemagne VL, Drago J, et al: In vivo measurement of vesicular monoamine transporter type 2 density in Parkinson disease with 18F-AV-133. J Nucl Med 2010; 51: 223-228.
14. Nurmi E, Bergman J, Eskola O, et al: Progression of dopaminergic hypofunction in striatal subregions in Parkinson's disease using [18F]CFT PET. Synapse 2003; 48: 109-115.
15. Wang J, Zuo CT, Jiang YP, et al: 18F-FP-CIT PET imaging and SPM analysis of dopamine transporters in Parkinson's disease in various Hoehn & Yahr stages. J Neurol 2007; 254: 185-190.
16. Kaasinen V, Ruottinen HM, Nagren K, Lehikoinen P, Oikonen V, Rinne JO: Upregulation of putaminal dopamine D2 receptors in early Parkinson's disease: a comparative PET study with [11C] raclopride and [11C]Nmethylspiperone. J Nucl Med 2000; 41: 65-70.
17. laFougere C, Poepperl G, Levin J, et al: The value of the dopamine D2/3-receptor ligand [18-F]-desmethoxyfallypride for the differentiation of idiopathic and nonidiopathic parkinsonian syndromes. J Nucl Med 2010; 51: 581-587.
18. Shinotoh H, Inoue O, Hirayama K, et al: Dopamine D1 receptors in Parkinson's disease and striatonigral degeneration: a positron emission tomography study. J Neurol Neurosurg Psychiatry 1993; 56: 467-472.
19. Ouchi Y, Kanno T, Okada H, et al: Presynaptic and postsynaptic dopaminergic binding densities in the nigrostriatal and mesocortical systems in early Parkinson's disease: a double-tracer positron emission tomography study. Ann Neurol 1999; 46: 723-731.
20. Cropley VL, Fujita M, Bara-Jimenez W, et al: Pre- and post-synaptic dopamine imaging and its relation with frontostriatal cognitive function in Parkinson disease: PET studies with [11C]NNC 112 and [18F]FDOPA. Psychiatry Res 2008; 163: 171-182.
21. Eckert T, Barnes A, Dhawan V, et al: FDG PET in the differential diagnosis of parkinsonian disorders. Neuroimage 2005; 26: 912-921.
22. Eggers C, Hilker R, Burghaus L, Schumacher B, Heiss WD: High resolution positron emission tomography demonstrates basal ganglia dysfunction in early Parkinson's disease. J Neurol Sci 2009; 276: 27-30.
23. Post KK, Singer C, Papapetropoulos S: Cardiac denervation and dysautonomia in Parkinson's disease: a review of screening techniques. Parkinsonism Relat Disord 2008; 14: 524-531.
24. Raffel DM, Koeppe RA, Little R, et al: PET measurement of cardiac and nigrostriatal denervation in Parkinsonian syndromes. J Nucl Med 2006; 47: 1769-1777.
25. Gerhard A, Pavese N, Hotton G, et al: In vivo imaging of microglial activation with [11C] (R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol Dis 2006; 21: 404-412.
26. Ouchi Y, Yagi S, Yokokura M, Sakamoto M: Neuroinflammation in the living brain of Parkinson's disease. Parkinsonism Relat Disord 2009; 15(suppl 3):S200-S204.
27. Fujimura Y, Kimura Y, Simeon FG, et al: Biodistribution and radiation dosimetry in humans of a new PET ligand, (18)F-PBR06, to image translocator protein (18 kDa). J Nucl Med 2010; 51: 145-149.
28. Brooks DJ: Imaging amyloid in Parkinson's disease dementia and dementia with Lewy bodies with positron emission tomography. Mov Disord 2009; 24(suppl 2):S742-S747.
29. Brooks DJ: Imaging non-dopaminergic function in Parkinson's disease. Mol Imaging Biol 2007; 9: 217-222.
30. Brooks DJ: Assessment of Parkinson's disease with imaging. Parkinsonism Relat Disord 2007; 13(suppl 3):S268-S275.
31. Antonini A, Vontobel P, Psylla M, et al: Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease. Arch Neurol 1995; 52: 1183-1190.
32. Jokinen P, Helenius H, Rauhala E, Bruck A, Eskola O, Rinne JO: Simple ratio analysis of 18F-fluorodopa uptake in striatal subregions separates patients with early Parkinson disease from healthy controls. J Nucl Med 2009; 50: 893-899.
33. Ribeiro MJ, Thobois S, Lohmann E, et al: A multitracer dopaminergic PET study of young-onset parkinsonian patients with and without parkin gene mutations. J Nucl Med 2009; 50: 1244-1250.
34. Pal PK, Leung J, Hedrich K, et al: [18F]-Dopa positron emission tomography imaging in early-stage, non-parkin juvenile parkinsonism. Mov Disord 2002; 17: 789-794.
35. Pavese N, Moore RY, Scherfler C, et al: In vivo assessment of brain monoamine systems in parkin gene carriers: a PET study. Exp Neurol 2010; 222: 120-124.
36. Rinne JO, Ruottinen H, Bergman J, Haaparanta M, Sonninen P, Solin O: Usefulness of a dopamine transporter PET ligand [(18)F] beta-CFT in assessing disability in Parkinson's disease. J Neurol Neurosurg Psychiatry 1999; 67: 737-741.
37. Bohnen NI, Albin RL, Koeppe RA, et al: Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease. J Cereb Blood Flow Metab 2006; 26: 1198-1212.
38. Brooks DJ: Morphological and functional imaging studies on the diagnosis and progression of Parkinson's disease. J Neurol 2000; 247(suppl 2):II11-II18.
39. Nagasawa H, Saito H, Kogure K, et al: 6-[18F] fluorodopa metabolism in patients with hemiparkinsonism studied by positron emission tomography. J Neurol Sci 1993; 115: 136-143.
40. Stoessl AJ: Positron emission tomography in premotor Parkinson's disease. Parkinsonism Relat Disord 2007; 13(suppl 3):S421-S424.
41. Laihinen A, Ruottinen H, Rinne JO, et al: Risk for Parkinson's disease: twin studies for the detection of asymptomatic subjects using [18F]6-fluorodopa PET. J Neurol 2000; 247(suppl 2):II110-II113.
42. Khan NL, Brooks DJ, Pavese N, et al: Progression of nigrostriatal dysfunction in a parkin kindred: an [18F]dopa PET and clinical study. Brain 2002; 125: 2248-2256.
43. Piccini P, Morrish PK, Turjanski N, et al: Dopaminergic function in familial Parkinson's disease: a clinical and 18F-dopa positron emission tomography study. Ann Neurol 1997; 41: 222-229.
44. Adams JR, van Netten H, Schulzer M, et al: PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. Brain 2005; 128: 2777-2785.
45. Morrish PK, Rakshi JS, Bailey DL, Sawle GV, Brooks DJ: Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET. J Neurol Neurosurg Psychiatry 1998; 64: 314-319.
46. Nurmi E, Ruottinen HM, Bergman J, et al: Rate of progression in Parkinson's disease: a 6-[18F]fluoro-L-dopa PET study. Mov Disord 2001; 16: 608-615.
47. Bruck A, Aalto S, Rauhala E, Bergman J, Marttila R, Rinne JO: A follow-up study on 6-[18F]fluoro-L-dopa uptake in early Parkinson's disease shows nonlinear progression in the putamen. Mov Disord 2009; 24: 1009-1015.
48. Whone AL, Watts RL, Stoessl AJ, et al: Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol 2003; 54: 93-101.
49. Marek K, Jennings D, Seibyl J: Dopamine agonists and Parkinson's disease progression: what can we learn from neuroimaging studies. Ann Neurol 2003; 53(suppl 3):S160-S166; discussion S166-S169.
50. Morrish PK: How valid is dopamine transporter imaging as a surrogate marker in research trials in Parkinson's disease? Mov Disord 2003; 18(suppl 7):S63-S70.
51. Fahn S, Oakes D, Shoulson I, et al: Levodopa and the progression of Parkinson's disease. N Engl J Med 2004; 351: 2498-2508.
52. Parkinson Study Group: Dopamine transporter brain imaging to assess the effects of pramipexole vs. levodopa on Parkinson disease progression. JAMA 2002; 287: 1653-1661.
53. Eckert T, Feigin A, Lewis DE, Dhawan V, Frucht S, Eidelberg D: Regional metabolic changes in parkinsonian patients with normal dopaminergic imaging. Mov Disord 2007; 22: 167-173.
54. Rinne JO, Laihinen A, Rinne UK, Nagren K, Bergman J, Ruotsalainen U: PET study on striatal dopamine D2 receptor changes during the progression of early Parkinson's disease. Mov Disord 1993; 8: 134-138.
55. Scherfler C, Khan NL, Pavese N, et al: Upregulation of dopamine D2 receptors in dopaminergic drug-naive patients with Parkin gene mutations. Mov Disord 2006; 21: 783-788.
56. Antonini A, Schwarz J, Oertel WH, Pogarell O, Leenders KL: Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: a study with positron emission tomography and [11C]raclopride. Mov Disord 1997; 12: 33-38.
57. Kaasinen V, Aalto S, Nagren K, Hietala J, Sonninen P, Rinne JO: Extrastriatal dopamine D(2) receptors in Parkinson's disease: a longitudinal study. J Neural Transm 2003; 110: 591-601.
58. Hirano S, Eckert T, Flanagan T, Eidelberg D: Metabolic networks for assessment of therapy and diagnosis in Parkinson's disease. Mov Disord 2009; 24(suppl 2):S725-S731.
59. Eckert T, Tang C, Eidelberg D: Assessment of the progression of Parkinson's disease: a metabolic network approach. Lancet Neurol 2007; 6: 926-932. (Pubitemid 47405003)
60. Cheesman AL, Barker RA, Lewis SJ, Robbins TW, Owen AM, Brooks DJ: Lateralisation of striatal function: evidence from 18F-dopa PET in Parkinson's disease. J Neurol Neurosurg Psychiatry 2005; 76: 1204-1210.
61. Nakagawa M, Kuwabara Y, Taniwaki T, et al: PET evaluation of the relationship between D2 receptor binding and glucose metabolism in patients with parkinsonism. Ann Nucl Med 2005; 19: 267-275.
62. Li D, Zuo C, Guan Y, et al: FDG-PET study of the bilateral subthalamic nucleus stimulation effects on the regional cerebral metabolism in advanced Parkinson disease. Acta Neurochir Suppl 2006; 99: 51-54.
63. Lin TP, Carbon M, Tang C, et al: Metabolic correlates of subthalamic nucleus activity in Parkinson's disease. Brain 2008; 131: 1373-1380.
64. Kalbe E, Voges J, Weber T, et al: Frontal FDG-PET activity correlates with cognitive outcome after STN-DBS in Parkinson disease. Neurology 2009; 72: 42-49.
65. Le Jeune F, Drapier D, Bourguignon A, et al: Subthalamic nucleus stimulation in Parkinson disease induces apathy: a PET study. Neurology 2009; 73: 1746-1751.
66. Venneti S, Lopresti BJ, Wiley CA: The peripheral benzodiazepine receptor (translocator protein 18 kDa) in microglia: from pathology to imaging. Prog Neurobiol 2006; 80: 308-322.
67. Ouchi Y, Yoshikawa E, Sekine Y, et al: Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann Neurol 2005; 57: 168-175.
68. Bartels AL, Willemsen AT, Doorduin J, de Vries EF, Dierckx RA, Leenders KL: [(11)C]- PK11195 PET: Quantification of neuroinflammation and a monitor of anti-inflammatory treatment in Parkinson's disease? Parkinsonism Relat Disord 16: 57-59.
69. Doder M, Rabiner EA, Turjanski N, Lees AJ, Brooks DJ: Tremor in Parkinson's disease and serotonergic dysfunction: an 11C-WAY 100635 PET study. Neurology 2003; 60: 601-605.
70. Kas A, Bottlaender M, Gallezot JD, et al: Decrease of nicotinic receptors in the nigrostriatal system in Parkinson's disease. J Cereb Blood Flow Metab 2009; 29: 1601-1608.
71. Meyer PM, Strecker K, Kendziorra K, et al: Reduced alpha4beta2 * -nicotinic acetylcholine receptor binding and its relationship to mild cognitive and depressive symptoms in Parkinson disease. Arch Gen Psychiatry 2009; 66: 866-877.
72. Bohnen NI, Muller ML, Koeppe RA, et al: History of falls in Parkinson disease is associated with reduced cholinergic activity. Neurology 2009; 73: 1670-1676.
73. Burn DJ, Sawle GV, Brooks DJ: Differential diagnosis of Parkinson's disease, multiple system atrophy, and Steele-Richardson-Olszewski syndrome: discriminant analysis of striatal 18F-dopa PET data. J Neurol Neurosurg Psychiatry 1994; 57: 278-284.
74. Antonini A, Leenders KL, Vontobel P, et al: Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease. Brain 1997; 120: 2187-2195.
75. Ghaemi M, Hilker R, Rudolf J, Sobesky J, Heiss WD: Differentiating multiple system atrophy from Parkinson's disease: contribution of striatal and midbrain MRI volumetry and multi-tracer PET imaging. J Neurol Neurosurg Psychiatry 2002; 73: 517-523.
76. Schreckenberger M, Hagele S, Siessmeier T, et al: The dopamine D2 receptor ligand 18Fdesmethoxyfallypride: an appropriate fluorinated PET tracer for the differential diagnosis of parkinsonism. Eur J Nucl Med Mol Imaging 2004; 31: 1128-1135.
77. Laureys S, Salmon E, Garraux G, et al: Fluorodopa uptake and glucose metabolism in early stages of corticobasal degeneration. J Neurol 1999; 246: 1151-1158.
78. Klaffke S, Kuhn AA, Plotkin M, et al: Dopamine transporters, D2 receptors, and glucose metabolism in corticobasal degeneration. Mov Disord 2006; 21: 1724-1727.
79. Brucke T, Djamshidian S, Bencsits G, Pirker W, Asenbaum S, Podreka I: SPECT and PET imaging of the dopaminergic system in Parkinson's disease. J Neurol 2000; 247(suppl 4):IV/2-7.
80. Kwon KY, Choi CG, Kim JS, Lee MC, Chung SJ: Diagnostic value of brain MRI and 18FFDG PET in the differentiation of Parkinsonian- type multiple system atrophy from Parkinson's disease. Eur J Neurol 2008; 15: 1043-1049.
81. Feng T, Wang Y, Ouyang Q, et al: Comparison of cerebral glucose metabolism between multiple system atrophy Parkinsonian type and Parkinson's disease. Neurol Res 2008; 30: 377-382.
82. Berding G, Schrader CH, Peschel T, et al: [Nmethyl 11C]meta- Hydroxyephedrine positron emission tomography in Parkinson's disease and multiple system atrophy. Eur J Nucl Med Mol Imaging 2003; 30: 127-131.
83. McKeith I, Mintzer J, Aarsland D, et al: Dementia with Lewy bodies. Lancet Neurol 2004; 3: 19-28. (Pubitemid 38018924)
84. Tatsch K: Imaging of the dopaminergic system in differential diagnosis of dementia. Eur J Nucl Med Mol Imaging 2008; 35(suppl 1):S51-S57.
85. Herholz K, Carter SF, Jones M: Positron emission tomography imaging in dementia. Br J Radiol 2007; 80:S160-S167.
86. Silverman DH: Brain 18F-FDG PET in the diagnosis of neurodegenerative dementias: comparison with perfusion SPECT and with clinical evaluations lacking nuclear imaging. J Nucl Med 2004; 45: 594-607.
87. Van Heertum RL, Tikofsky RS: Positron emission tomography and single-photon emission computed tomography brain imaging in the evaluation of dementia. Semin Nucl Med 2003; 33: 77-85.
88. Hu XS, Okamura N, Arai H, et al: 18F-fluorodopa PET study of striatal dopamine uptake in the diagnosis of dementia with Lewy bodies. Neurology 2000; 55: 1575-1577.
89. Gilman S, Koeppe RA, Little R, et al: Striatal monoamine terminals in Lewy body dementia and Alzheimer's disease. Ann Neurol 2004; 55: 774-780.
90. Walker Z, Costa DC, Janssen AG, Walker RW, Livingstone G, Katona CL: Dementia with lewy bodies: a study of post-synaptic dopaminergic receptors with iodine-123 iodobenzamide single-photon emission tomography. Eur J Nucl Med 1997; 24: 609-614.
91. Kemppainen N, Ruottinen H, Nagren K, Rinne JO: PET shows that striatal dopamine D1 and D2 receptors are differentially affected in AD. Neurology 2000; 55: 205-209.
92. Piggott MA, Marshall EF, Thomas N, et al: Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution. Brain 1999; 122: 1449-1468.
93. Shimada H, Hirano S, Shinotoh H, et al: Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET. Neurology 2009; 73: 273-278.
94. Klein JC, Eggers C, Kalbe E, et al: Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo. Neurology 2010; 74: 885-892.